Transaction · 0001231919-26-001135

GADICKE ANSBERT

GADICKE ANSBERT, 10% Owner, reported an open-market or private sale at Entrada Therapeutics, Inc. involving 44259.000000 shares for an estimated $309370.41. Reported holdings after the transaction were 4231434.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
TRDAEntrada Therapeutics, Inc.
Filing timeAug 31
Trade dateAug 31, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$7.05
Pre-filing
1mo ago1w ago1d ago -0.7%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

TRDA price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TRDA since 2026-08-31Filed 3 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001231919-26-001135
Common Stock
Transaction date
Aug 31, 2026
Filed Aug 31, 2026, 10:25 PM · 0d delay
Shares
44.2k sh
$699 per share
Estimated value
-$30.9M
Computed from shares × price
Holdings after
4.23M sh
Indirect · See Footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Repeat Seller
+4score
Filing-only score

+4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014")…

  2. F2

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

  3. F3

    The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.

  4. F4

    Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

  5. F5

    The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.

  6. F6

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

  7. F7

    The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.

  8. F8

    The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.

  9. F9

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of th…

  10. F10

    The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.

Original filing · 0001231919-26-001135
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TRDA